Subtype
Female Reproductive System Carcinoma
CI-CAN-00002685Explore in graph →
- NCIt
- C181162
Loading cancer entity…
Subtype
CI-CAN-00002685Explore in graph →
Variants & evidence
57 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PTEN Mutation1 | ||||||||
| Everolimus | Endometrial Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | accepted | EID1232Tumors from 35 patients (12 with partial response or stable disease) with advanced endometrial carcinoma were assessed for PTEN mutational status, revealing 12 tumors with non-identical PTEN gene muta… (full text at CIViC) PMID 23238879 · Trédan et al., 2013 · Open in CIViC | civic |
| NRG1 Fusion2 | ||||||||
| Afatinib | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID7489A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC | civic |
| Erlotinib + LumretuzumabCombination | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID7495Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC) PMID 30268483 · Kim et al., 2018 · Open in CIViC | civic |
| SMARCA4 Loss1 | ||||||||
| Abemaciclib + Palbociclib + RibociclibSubstitutes | Ovarian Small Cell Carcinoma | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID7154Inactivating mutations in SMARCA4 underlie small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). The authors show that loss of SMARCA4 leads to downregulation of Cyclin D1 and deficient cell… (full text at CIViC) PMID 30718512 · Xue et al., 2019 · Open in CIViC | civic |
| STMN1 EXPRESSION1 | ||||||||
| Paclitaxel | Endometrial Carcinoma | Predictive | B | Supports Resistance | 3 | accepted | EID85533 patients were retrospectively analyzed for Stathmin expression by IHC. High protein expression was correlated with poor response to paclitaxel but not other chemotherapy. The authors supported this… (full text at CIViC) PMID 24587245 · Werner et al., 2014 · Open in CIViC | civic |
| High1 | ||||||||
| Carboplatin + PaclitaxelCombination | Ovarian Serous AdenocarcinomaALIAS | Predictive | C | Supports Resistance | 3 | submitted | EID13010In a retrospective cohort of 16 patients treated with primary debulking surgery followed by platinum-taxane chemotherapy (carboplatin and paclitaxel), patients classified as platinum-resistant exhibit… (full text at CIViC) PMID 35093146 · Yang et al., 2022 · Open in CIViC | civic |
| TP53 R213*1 | ||||||||
| (predisposing) | Salivary Gland Mucinous Adenocarcinoma | Predisposing | E | Supports Pathogenic | 3 | submitted | EID7321As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC) PMID 28249646 · Panaccione et al., 2017 · Open in CIViC | civic |
Data updated 12 minutes agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.